Holding(s) in Company

18 May 2006 16:27

Cambridge Antibody Tech Group PLC18 May 2006 NOTIFICATION OF MAJOR INTERESTS IN SHARES 1. Name of company Cambridge Antibody Technology Group plc 2. Name of shareholder having a major interest The Goldman Sachs Group Inc. 3. Please state whether notification indicates that it is in respect of holdingof the shareholder named in 2 above or in respect of a non-beneficial interestor in the case of an individual holder if it is a holding of that person'sspouse or children under the age of 18 Goldman Sachs Securities (Nominees) Limited non beneficialThe Depositary Trust Company, New York non beneficialGoldman Sachs Securities (Nominees) Limited beneficialThe Depositary Trust Company, New York beneficialGoldman Sachs International (CREST a/c CREPTEMP) beneficialGoldman Sachs JBWere Managed Funds Limited beneficial 4. Name of the registered holder(s) and, if more than one holder, the number ofshares held by each of them Goldman Sachs Securities (Nominees) Limited 873,435The Depositary Trust Company, New York 475,065Goldman Sachs Securities (Nominees) Limited 1,400The Depositary Trust Company, New York 200Goldman Sachs International (CREST a/c CREPTEMP) 871,289Goldman Sachs JBWere Managed Funds Limited 87,360 5. Number of shares / amount of stock acquired not disclosed 6. Percentage of issued class not known 7. Number of shares / amount of stock disposed None 8. Percentage of issued class N/A 9. Class of security Ordinary 10 pence shares 10. Date of transaction 15 May 2006 11. Date company informed 18 May 2006 12. Total holding following this notification 2,308,749 13. Total percentage holding of issued class following this notification 4.34% 14. Any additional information None 15. Name of contact and telephone number for queries Justin Hoskins 01223 898589 16. Name and signature of authorised company official responsible for makingthis notification Justin Hoskins, Company Secretary Date of notification 18 May 2006 The FSA does not give any express or implied warranty as to the accuracy of thisdocument or material and does not accept any liability for error or omission.The FSA is not liable for any damages (including, without limitation, damagesfor loss of business or loss of profits) arising in contract, tort or otherwisefrom the use of or inability to use this document, or any material contained init, or from any action or decision taken as a result of using this document orany such material. This information is provided by RNS The company news service from the London Stock Exchange